These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28319404)

  • 1. Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8
    Karuturi BVK; Tallapaka SB; Yeapuri P; Curran SM; Sanderson SD; Vetro JA
    Mol Pharm; 2017 May; 14(5):1469-1481. PubMed ID: 28319404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.
    Tallapaka SB; Karuturi BVK; Yeapuri P; Curran SM; Sonawane YA; Phillips JA; David Smith D; Sanderson SD; Vetro JA
    Int J Pharm; 2019 Jun; 565():242-257. PubMed ID: 31077762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.
    Karuturi BV; Tallapaka SB; Phillips JA; Sanderson SD; Vetro JA
    Clin Immunol; 2015 Dec; 161(2):251-9. PubMed ID: 26111481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge.
    Ye M; Morello CS; Spector DH
    J Virol; 2002 Mar; 76(5):2100-12. PubMed ID: 11836387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).
    Morello CS; Cranmer LD; Spector DH
    J Virol; 2000 Apr; 74(8):3696-708. PubMed ID: 10729145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs.
    Holtappels R; Pahl-Seibert MF; Thomas D; Reddehase MJ
    J Virol; 2000 Dec; 74(24):11495-503. PubMed ID: 11090146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface Modification of Biodegradable Microparticles with the Novel Host-Derived Immunostimulant CPDI-02 Significantly Increases Short-Term and Long-Term Mucosal and Systemic Antibodies against Encapsulated Protein Antigen in Young Naïve Mice after Respiratory Immunization.
    Parriott JE; Stewart JP; Smith DD; Curran SM; Bauer CD; Wyatt TA; Phillips JA; Lyden E; Thiele GM; Vetro JA
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L.
    Bachmann MF; Wolint P; Schwarz K; Jäger P; Oxenius A
    J Immunol; 2005 Oct; 175(7):4686-96. PubMed ID: 16177116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. gB co-immunization with GP96 enhances pulmonary-resident CD8 T cells and exerts a long-term defence against MCMV pneumonitis.
    Guo B; Xu P; Chai D; Cao L; Liu L; Song T; Hu S; Chen Y; Yan X; Xu T
    J Cell Mol Med; 2020 Dec; 24(24):14426-14440. PubMed ID: 33155438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal CD8+ T cell responses induced by an MCMV based vaccine vector confer protection against influenza challenge.
    Zheng X; Oduro JD; Boehme JD; Borkner L; Ebensen T; Heise U; Gereke M; Pils MC; Krmpotic A; Guzmán CA; Bruder D; Čičin-Šain L
    PLoS Pathog; 2019 Sep; 15(9):e1008036. PubMed ID: 31525249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication.
    Morello CS; Ye M; Spector DH
    J Virol; 2002 May; 76(10):4822-35. PubMed ID: 11967299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles.
    Kabiri M; Sankian M; Sadri K; Tafaghodi M
    Eur J Pharm Biopharm; 2018 Dec; 133():321-330. PubMed ID: 30408519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidized Carbon Nanosphere-Based Subunit Vaccine Delivery System Elicited Robust Th1 and Cytotoxic T Cell Responses.
    Sawutdeechaikul P; Cia F; Bancroft G; Wanichwecharungruang S; Sittplangkoon C; Palaga T
    J Microbiol Biotechnol; 2019 Mar; 29(3):489-499. PubMed ID: 30691253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection.
    Panagioti E; Redeker A; van Duikeren S; Franken KL; Drijfhout JW; van der Burg SH; Arens R
    PLoS Pathog; 2016 Sep; 12(9):e1005895. PubMed ID: 27637068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape.
    Hengel H; Lucin P; Jonjić S; Ruppert T; Koszinowski UH
    J Virol; 1994 Jan; 68(1):289-97. PubMed ID: 8254740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8
    Knight FC; Gilchuk P; Kumar A; Becker KW; Sevimli S; Jacobson ME; Suryadevara N; Wang-Bishop L; Boyd KL; Crowe JE; Joyce S; Wilson JT
    ACS Nano; 2019 Oct; 13(10):10939-10960. PubMed ID: 31553872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.
    Belyakov IM; Ahlers JD
    Curr Med Chem; 2011; 18(26):3953-62. PubMed ID: 21824096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y; Bai O; Zhang H; Li W; Xiang J
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
    Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
    Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.